Hypoxia and Hypoxia-Inducible Factors in Lymphedema

Frontiers in Pharmacology

Gregg L. Semenza¹  Stanley G. Rockson²  Mark R. Nicolls²  Wen Tian²  Dongeon Kim²  Alexander S. McQuiston²  Ryan Vinh²  Xinguo Jiang² 

[1] Departments of Pediatrics, Medicine, Oncology, Radiation Oncology, and Biological Chemistry, and McKusick-Nathans Institute of Genetic Medicine, Vascular Program, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, United States;Stanford University School of Medicine, Stanford, CA, United States;VA Palo Alto Health Care System, Palo Alto, CA, United States;

关键词: HIF;    lymphedema;    inflammation;    lymphangiogensis;    hypoxia;   

DOI  :  10.3389/fphar.2022.851057

来源: DOAJ

【 摘 要 】

Lymphedema is a chronic inflammatory disorder characterized by edema, fat deposition, and fibrotic tissue remodeling. Despite significant advances in lymphatic biology research, our knowledge of lymphedema pathology is incomplete. Currently, there is no approved pharmacological therapy for this debilitating disease. Hypoxia is a recognized feature of inflammation, obesity, and fibrosis. Understanding hypoxia-regulated pathways in lymphedema may provide new insights into the pathobiology of this chronic disorder and help develop new medicinal treatments.

【 授权许可】

Unknown